JB Chemicals & Pharma reports Q2 PAT of Rs98cr up by 32% yoy; Stock trades in green

The company records revenue growth of 34% yoy to Rs593cr in Q2FY22.

November 12, 2021 11:16 IST | India Infoline News Service
Quarterly Results
JB Chemicals & Pharmaceuticals Limited on Thursday reported higher consolidated profit at Rs98cr in the quarter ended September 30, 2021, against Rs74cr in the same quarter of last fiscal, an increase of 32% yoy. The company’s revenue increased 34% yoy to Rs593cr in Q2FY22 from Rs443.56cr in Q2FY21.

Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 27% to Rs140cr as compared to Rs110cr. Adjusted EBITDA increased by 40 % to Rs154cr.

For the first half of the financial year 2021-22, the Company recorded revenue of Rs1199cr as compared to Rs966cr, registering growth of 24% over the corresponding period ended September 30, 2020. Operating EBITDA increased by 14 % to Rs303cr as compared to Rs266cr. Adjusted EBITDA increased by 19.2 % to Rs317cr.  Profit after Tax stood at Rs217cr as compared to Rs193cr, registering growth of 12% yoy.

At around 11.20 am, JB Chemicals & Pharmaceuticals Ltd was trading at Rs1,664.70 per piece up by Rs7.3 or 0.44% from its previous closing of Rs1,657.40 per piece on the BSE.

“Our strong operational performance has led to market beating growth in India and steady performance in international business despite pandemic related issues and supply chain uncertainties,” Nikhil Chopra, CEO and Wholetime Director, JBCPL, said.

He further added “During the past one year, several initiatives including the realigned Go-To-Market model, diversification into complimentary therapies and new launches have helped us sustain our growth momentum in India leading to market share gains and rank improvement.

While international business is confronted with external market challenges, our key markets like South Africa and the US have done well and Russia is showing signs of steady revival. We are working aggressively on expanding our offerings in the international market by reorienting our R&D and aggressively pursuing business development opportunities. Going forward, our priority will be to further optimise our cost structure and continue to build on the revenue momentum in line with our strategic priorities.”

OPEN A DEMAT ACCOUNT & Get FREE Benefits worth 10,000

FREE Benefits worth 10,000



The average score for Prestige Estates Projects Limited stands at 4 against 6, three months back.

Prestige Estates Projects Limited is engaged in the business of real estate development. The Company’s principal products/services include Development and construction



Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity